三诺收购美国PTS，为慢病提供更多解决方案

[May 2^nd, 2016] (Changsha, China) – Sinocare Inc. [San Nuo Sheng Wu, SHE: 300298], announced today it has signed a definitive purchase agreement with privately-held PTS Diagnostics, under which Sinocare will acquire PTS Diagnostics forup to $200 million in cash including contingent considerations of up to $90 million for the successful accomplishment of certain milestones.  PTS Diagnostics is a U.S.-based manufacturer of point-of-care biometric testing devices, including the CardioChek® family of analyzers, A1CNow® systems, and PTS Detect™ cotinine systems. The company's manufacturing facilities are principally located in Indianapolis, IN and Sunnyvale, CA.

[2016年5月2日]（中国，长沙）三诺生物传感股份有限公司[股票代码：300298，股票简称：三诺生物]于今日宣布其已与私人控股公司PTS诊断签署了最终并购协议，根据协议安排，三诺为收购PTS诊断将支付#!高达2亿美元的现金，其中包括不超过9，000万美元附条件的业务收入目标达成付款计划。PTS诊断是一家位于美国的即时检测（POCT-Point of Care Testing）生物检测设备制造企业，产品包括CardioChek®系列分析仪、A1CNow®系列测试系统和PTS Detect™尼古丁检测系统。公司生产基地主要位于印第安纳州印第安纳波利斯市和加利福尼亚州森尼维尔市。

Shaobo Li, Chairman and CEO of Sinocare commented, “Sinocare is dedicated to the innovation of biosensor technology and has been providing high quality products and services to people with diabetes and other chronic diseases. Through continuous innovation, PTS Diagnostics has become the market leader of lipid, A1C and other important point of care biometric testing. We know Sinocare and PTS Diagnostics have a shared vision and mission to improve the quality of life for our users.  We commend and respect the achievements of the PTS management team and employees, and we are confident that they will be able to continue to deliver and achieve our common goals. We will continue to grow our business and explore opportunities globally and we will provide more innovative and systematic solutions to fight chronic diseases which allow people with diabetes and other chronic diseases live better and healthier lives.”

三诺生物董事长兼总经理李少波先生说：“三诺生物致力于应用创新生物传感技术为糖尿病及其他慢性疾病患者提供高质量的产品和服务。通过持续创新，PTS诊断已成为血脂、糖化血红蛋白和其他重要即时生物检测产品市场中的领导企业。三诺生物和PTS诊断在改善用户生活质量方面拥有共同的愿景和使命。我们钦佩和尊重PTS管理团队和员工已取得的成就，并且对他们继续实现双方的共同目标充满信心。我们将继续壮大彼此的业务，寻求更多的全球发展机会，并为慢性疾病的防治提供更多创新性、系统性的解决方案，让糖尿病及其他慢性疾病患者更加健康地生活。”

“PTS Diagnostics has a proven track record of driving innovation and efficiency in the point of care biometric testing category.  We are quite pleased and excited by the many future opportunities that now open for us as a part of the Sinocare Group, as together we will greatly expand our mutual global reach. We share a vision of innovation and creativity, and together we will make our various solutions available to a much larger customer base, driving action and connecting more people to improved outcomes.  Our biometric connectivity and information platform, PTS Connect™, continues to solve significant data management problems for healthcare professionals,” said Robert Huffstodt, President and CEO of PTS Diagnostics.  “PTS Diagnostics’ core product portfolio of lipid and HbA1c testing systems also integrate well with Sinocare's focus on glucose monitoring.  Our combined company will provide unmatched access to information that will help improve diagnosis and monitoring of multiple chronic diseases.   Together, our future will be centered on transforming preventative medicine, biometric testing, and connectivity by providing fast, easy, portable, and accurate medical devices and information management systems to individuals and healthcare professionals.”

“PTS诊断在POCT生物检测领域所取得业绩有目共睹。对于诸多未来的机遇正向我们敞开，作为三诺集团的一员我们感到非常高兴和激动，我们将共同扩大彼此的国际影响力。双方在产品创新创造方面拥有共同愿景，我们将会一同为更广泛的用户群体提供多种解决方案，通过驱动和连接更多的客户，改善他们的健康状况。我们的生物检测连接和信息管理平台PTS Connect™能为医疗保健专业人员持续解决重要的数据管理问题。”PTS董事长兼总经理Robert Huffstodt先生说。“PTS诊断的核心产品组合（血脂和糖化血红蛋白检测系统）也会同三诺生物所聚焦的血糖监测产品进行良好的整合。双方合并后的公司能实现无可比拟的信息共享，这将有助于改善多种慢性疾病的诊断和监测。未来，双方将共同通过为个人和医疗保健专业人员提供快速、简便、便携和准确的医疗设备和信息管理系统，专注于改变预防医学、生物检测和检测数据连接等业务领域。”

Subject to the satisfaction of certain conditions, the transaction is expected to be completed within one hundred and twenty days.

如本次交易的相关条件能得以满足，交易预计将在协议签署后的120天内完成。

Evercore is acting as exclusive financial advisor to Sinocare.  J.P. Morgan Securities LLC is acting as exclusive advisor to PTS Diagnostics.

此次交易中，Evercore担任三诺生物的独家财务顾问，摩根大通证券则作为PTS诊断的独家顾问。

About PTS Diagnostics

关于PTS诊断

PTS Diagnostics is an innovative, global, point-of-care diagnostics solutions provider that partners with patients and healthcare professionals to provide the right information at the right time to make the right decision. The company's name represents the three pillars upon which it has built its long-term success: People, Technology and Service. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, distributes and markets products for distribution in more than 135 countries around the world. The company's signature products include CardioChek^®family of lipid and glucose analyzers & products, and A1CNow^®+ systems, portable analyzers that in just 5 minutes provides an HbA1c measurement.  In addition, PTS Diagnostics recently launched the portable tobacco-detection device, PTS Detect cotinine system. Further, the company offers technology that makes biometric device connectivity flexible and information management simple with its PTS Connect™ solutions. 

PTS诊断是一家创新的、全球化的POCT诊断解决方案供应商，作为病人和医疗保健专业人员的伙伴，公司为他们做出正确判断而适时提供所需的检测结果。PTS诊断的公司名称代表了其长远发展所依赖的三大支柱：人（People）、技术（Technology）和服务（Service）。公司总部位于美国印第安纳州印第安纳波利斯市，产品营销网络覆盖全球135个国家和地区。公司主要产品包括CardioChek®系列血脂、血糖分析监测设备和A1CNow®便携式分析设备（该产品能在5分钟内提供糖化血红蛋白的检测结果）。此外，PTS诊断近期还推出了便携式尼古丁检测设备——PTS可替宁测试系统。未来，公司将提供具备灵活接入技术和信息管理功能的生物检测设备——PTS Connect™解决方案。

About Sinocare

关于三诺

Sinocare Group consists of Sinocare, Inc., Trividia Health and its affiliates. Sinocare, Inc., headquartered in Changsha, China, is fully dedicated to the innovation of Biosensor technology and promoting diabetic self-management by using blood glucose monitoring systems in China. Founded in 2002, the company has been providing high quality and low cost blood glucose monitoring systems to the Chinese market and has been listed as one of Asia's 200 Best Under A Billion Company.

三诺集团由三诺生物传感股份有限公司、Trividia Health及其附属机构组成。三诺生物传感股份有限公司总部位于中国长沙，致力于应用创新生物传感技术，促进血糖监测产品在中国的普及推广。公司成立于2002年，为中国市场提供高性价比的血糖监测产品，并入选“福布斯2015亚洲中小上市企业200强”榜单。